Fan Arthur Yin, Lao Lixing, Zhang Rui-xin, Zhou An-nan, Berman Brian M
Center for Integrative Medicine, University of Maryland, Baltimore, MD 21201, USA.
Zhong Xi Yi Jie He Xue Bao. 2010 May;8(5):438-47. doi: 10.3736/jcim20100507.
To investigate the safety of oral administration of Modified Huo Luo Xiao Ling Dan (HLXLD), a compound traditional Chinese herbal medicine.
The toxicological information of HLXLD and its individual constituent herbs was searched in cintcm or TCMlars (www.cintcm.com), PubMed (MEDLINE), Chinese Herbal Medicine (1999) and WHO Monographs on Selected Medicinal Plants (Vol. I- III). Single-dose acute toxicity was assessed by using the highest possible dosage. Motor function test was used to determine whether the herbal formula might cause motor impairment. Nine-day HLXLD repeat-dose sub-chronic toxicity/adverse effects, and 42-day chronic toxicity/adverse effects in rats were also assessed.
The literature searches showed that HLXLD and its eleven ingredient herbs had no side/adverse effects listed in the traditional Chinese medicine literature. Under the dosages proposed in the formula, the HLXLD formula had no side/adverse effects according to MEDLINE, Chinese Herbal Medicine and WHO Monographs on Selected Medicinal Plants. The studies in rats showed: (1) in single-dose acute toxicity assessment, the maximal feasible single oral dose, 9.20 g/kg HLXLD, showed no significant effect on clinical signs, or body weight and mortality over a 14-day period in rats; (2) during motor function test, nine-day repeat-dose of daily HLXLD treatment at 4.60 g/kg did not cause motor impairment; (3) in nine-day HLXLD repeat-dose sub-chronic toxicity/adverse effects assessment, there were no noticeable abnormal behavioral changes or obvious adverse reactions and signs in complete Freund's adjuvant inflamed rats (highest observed dosage: 4.60 g/kg), and no noticeable adverse effects were observed during, or 14 days after nine-day treatment at 4.60 g/kg in non-inflamed rats; (4) during 42-day chronic toxicity/adverse effects assessments, no noticeable abnormal behavioral changes, no obvious adverse reactions and signs were observed in normal rats administered with HLXLD at a dose of 2.30 g/kg and the values of serum biochemistry and histopathology were in normal range.
Both existing information and animal data support that Modified HLXLD is a safe herbal product for clinical application.
研究复方中药改良活络效灵丹(HLXLD)口服给药的安全性。
在中药综合信息数据库(cintcm)或中医大辞典(www.cintcm.com)、PubMed(MEDLINE)、《中草药》(1999年)以及世界卫生组织《选定药用植物专著》(第一至三卷)中检索HLXLD及其单味组成草药的毒理学信息。采用最大可能剂量评估单剂量急性毒性。通过运动功能测试来确定该中药配方是否可能导致运动功能受损。还评估了HLXLD在大鼠中的9天重复剂量亚慢性毒性/不良反应以及42天慢性毒性/不良反应。
文献检索表明,HLXLD及其11味组成草药在传统中药文献中均无副作用/不良反应记载。根据MEDLINE、《中草药》以及世界卫生组织《选定药用植物专著》,在配方建议剂量下,HLXLD配方无副作用/不良反应。大鼠研究显示:(1)在单剂量急性毒性评估中,最大可行单口服剂量9.20 g/kg HLXLD对大鼠14天内的临床体征、体重及死亡率无显著影响;(2)在运动功能测试期间,4.60 g/kg的HLXLD每日重复给药9天未导致运动功能受损;(3)在9天HLXLD重复剂量亚慢性毒性/不良反应评估中,完全弗氏佐剂致炎大鼠(最高观察剂量:4.60 g/kg)未出现明显的异常行为变化或明显不良反应及体征,非致炎大鼠在4.60 g/kg给药9天期间及给药后14天未观察到明显不良反应;(4)在42天慢性毒性/不良反应评估中,给予2.30 g/kg HLXLD的正常大鼠未出现明显异常行为变化、无明显不良反应及体征,血清生化和组织病理学值均在正常范围内。
现有信息及动物实验数据均支持改良HLXLD是一种临床应用安全的草药产品。